[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368255-105":59,"doc-detail-368255-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rna-binding-proteins-as-therapeutic-targets-in-cancer-review-article","RNA-binding proteins as therapeutic targets in cancer - Review Article","","RNA-binding proteins (RBPs) act as key regulators of cancer progression by reshaping gene-expression programs that can either promote or suppress tumorigenesis. Their capacity to modulate expression patterns has made RBPs attractive candidates for anti-cancer therapeutics. This mini-review surveys current RBP-targeted treatment strategies through five representative examples—eIF4F, FTO, SF3B1, RBM39, and nucleolin—while addressing challenges such as complex RBP regulatory networks, potential off-target effects, and the need for more selective targeting approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rna-binding-proteins-as-therapeutic-targets-in-cancer-review-article/368255/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rna-binding-proteins-as-therapeutic-targets-in-cancer-review-article/368255.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are RNA-binding proteins considered promising targets for cancer therapy?","Question",{"text":112,"@type":113},"RBPs regulate many cancer-related gene expression programs and influence multiple hallmarks of cancer, making them suitable for therapeutic intervention.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What makes developing drugs against RNA-binding proteins difficult?",{"text":117,"@type":113},"Many RBPs lack classic druggable pockets, contain unstructured regions, and share structural homology, while their multifunctional, networked behavior complicates predicting downstream effects.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic strategies are highlighted in this review?",{"text":121,"@type":113},"The review summarizes current approaches using five examples—eIF4F, FTO, SF3B1, RBM39, and nucleolin—and discusses targeting methods such as antisense oligonucleotides and other specificity-improving strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368255,1790693913,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","REVIEW ARTICLE     \nRNA-binding proteins as therapeutic targets in cancer  \nJennifer Jungfleisch a and Fátima Gebauer a,b  \naCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; bUniversitat Pompeu Fabra (UPF), Barcelona, Spain  \nABSTRACT  \nRNA-binding proteins (RBPs) have emerged as critical regulators of cancer progression, influencing virtually all hallmarks of cancer. Their ability to modulate gene expression patterns that promote or inhibit tumorigenesis has positioned RBPs as promising targets for novel anti-cancer therapies. This mini-review summarizes the current state of RBP-targeted cancer treatments, focusing on five examples, eIF4F, FTO, SF3B1, RBM39 and nucleolin. We highlight the diversity of current targeting approaches and discuss ongoing challenges including the complexity of RBP regulatory networks, potential off-target effects and the need for more specific targeting methods. By assessing the future potential of novel therapeutic avenues, we provide insights into the evolving landscape of cancer treatment and the critical role RBPs may play in next-generation therapeutics.  \nARTICLE HISTORY  \nRevised 4 February 2025 Accepted 17 February 2025  \nKEYWORDS  \nRNA-binding proteins; cancer; therapeutic targets; ASO; SMI; aptamer; molecular glue  \nIntroduction  \nRNA-binding proteins (RBPs) are crucial regulators of gene expression, orchestrating every phase of the mRNA lifecycle, from transcription and splicing to transport, stability and translation [ 1] . These versatile molecules dynamically interact with hundreds of RNA transcripts, both coding and noncoding, forming intricate regulatory networks that maintain cellular homoeostasis. RBPs bind to RNA forming ribonucleoprotein particles (RNPs) . Recent research has revealed that the influence of these RNPs extends far beyond mRNA metabolism, including the assembly of membraneless compartments and the control of intracellular signalling [2–4] . The critical role RBPs play in cellular function underscores their significance in disease including, among others, neurodegenerative disease, autoimmune conditions, cardiovascular disease and cancer, pointing towards the targeting of RNA-protein complexes as a promising therapeutic avenue [5,6] .  \nIn recent years, significant efforts have been made to identify novel RBPs and generate a comprehensive map of these proteins [ 1,5,7]. Unbiased large-scale studies, such as RNA interactome capture (RIC), have dramatically expanded our knowledge of the RBP landscape [8,9]. To date, more than 4000 RBPs have been identified, highlighting the complexity and diversity of this protein family [5]. However, despite their abundance and critical functions, the exploration of RBPs as therapeutic targets remains in its infancy. This lag in development can be attributed to several factors that historically rendered RBPs ‘undruggable’. One significant factor is that RBPs often lack the well-defined hydrophobic pockets typically found in enzymes, making traditional drug design less effective. Compounding this issue is the frequent presence of unstructured regions, further complicating drug design efforts [ 10]. Moreover, the high structural homology  \nshared by several RBPs presents an important challenge in developing specific targeting strategies. Adding to these hurdles, the multifunctional nature of RBPs and their networking capacity makes it difficult to predict the downstream effects of RBPdirected therapies. RBPs interact with multiple RNA targets and other proteins within functionally related units known as ‘RNA regulons’ [ 11, 12], complicating efforts to modulate one RBP without causing unintended side effects across the entire network. To address this challenge, researchers are developing sophisticated approaches that consider the context of RBP–RNA interactions. By taking into account both the secondary structure of the RNA and the nucleotides flanking the core-binding motif, whi","cbCaidggvf7H55Ck","https://ap.wps.com/l/cbCaidggvf7H55Ck","pdf",869873,"English","# Introduction\n## Challenges in drugging RNA-binding proteins\n## Examples of therapeutic targeting approaches","[{\"question\":\"Why are RNA-binding proteins considered promising targets for cancer therapy?\",\"answer\":\"RBPs regulate many cancer-related gene expression programs and influence multiple hallmarks of cancer, making them suitable for therapeutic intervention.\"},{\"question\":\"What makes developing drugs against RNA-binding proteins difficult?\",\"answer\":\"Many RBPs lack classic druggable pockets, contain unstructured regions, and share structural homology, while their multifunctional, networked behavior complicates predicting downstream effects.\"},{\"question\":\"Which therapeutic strategies are highlighted in this review?\",\"answer\":\"The review summarizes current approaches using five examples—eIF4F, FTO, SF3B1, RBM39, and nucleolin—and discusses targeting methods such as antisense oligonucleotides and other specificity-improving strategies.\"}]","RNA-binding proteins as therapeutic targets in cancer - Review Article | PDF",1790175884,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/272c0dff77b65cc2b642aae38cf7c37f.webp",983,1280,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f78a1031809b343707f354fa3f4b734b.webp",982,1278,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7a556c7256bfad8f8ff87fba2dbfb05.webp",981,1277,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b3dd51d57f1ca9e2153c602735d9e97.webp",980,1276]